文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-AlF标记PSMA配体用于PSMA表达移植瘤显像的体外与体内特性

In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.
PubMed 文献 · J Nucl Med · 2019-01-17

本研究以18F-AlF络合方式标记PSMA-11,并与68Ga-PSMA-11对比其在PSMA表达LNCaP细胞及LS174T-PSMA荷瘤鼠中的内化、生物分布与PET/CT显像表现。结果显示两者肿瘤摄取相近且均可显像移植瘤,但18F-AlF-PSMA-11在水中稳定性有限、骨摄取较高,可能影响小骨转移灶的显示。

要点

  • 18F-AlF-PSMA-11在25 mM NH4OAc(pH 6.9)中相对稳定,纯化后180分钟放化纯度92.5%。
  • 注药后2小时肿瘤摄取18F-AlF-PSMA-11为10.8±2.3 %ID/g,与68Ga-PSMA-11的7.9±1.3 %ID/g差异无统计学意义(P>0.05)。
  • 18F-AlF-PSMA-11肾脏摄取低于68Ga-PSMA-11,但骨摄取较高且与注药时放化纯度相关。

核心结论

  • 18F-AlF-PSMA-11可在pH 6.9的NH4OAc中直接以氟化铝标记制备,内化率高,肿瘤摄取与68Ga-PSMA-11相近并可显像PSMA表达肿瘤。
  • 其肾脏摄取低于68Ga-PSMA-11可能有利于肿瘤检出,但稳定性有限及随之产生的骨内Al18F摄取可能妨碍小前列腺癌骨转移灶的可视化。

研究设计与样本

  • 体外比较18F-AlF-PSMA-11与68Ga-PSMA-11在PSMA表达LNCaP肿瘤细胞中的内化动力学。
  • 在荷PSMA表达皮下LS174T-PSMA瘤的雄性BALB/c裸鼠中,比较18F-AlF-PSMA-11(0.26 nmol/鼠,8-9 MBq/鼠)与68Ga-PSMA-11注药后1和2小时的生物分布。
  • 注药后1和2小时行18F-AlF-PSMA-11与68Ga-PSMA-11 PET/CT显像。

主要发现

  • 18F-AlF-PSMA-11在水中不稳定,纯化后即刻放化纯度64.5%,纯化后120分钟为52.7%。
  • 在25 mM NH4OAc(pH 6.9)中放化纯度由纯化时98.5%降至纯化后60、120、180分钟的96.3%、94.7%、92.5%。
  • 注药后2小时肿瘤摄取最高:18F-AlF-PSMA-11为10.8±2.3 %ID/g,68Ga-PSMA-11为7.9±1.3 %ID/g(P>0.05)。
  • 注药后2小时肾脏摄取峰值:18F-AlF-PSMA-11为43.5±5.7 %ID/g,68Ga-PSMA-11为105.8±13.8 %ID/g(P<0.05)。
  • 18F-AlF-PSMA-11骨摄取注药后1小时为3.3±0.6 %ID/g、2小时为5.0±0.6 %ID/g,且取决于注药时放化纯度;68Ga-PSMA-11骨摄取1和2小时均为0.1±0.0 %ID/g。

关键数值与推荐

  • 18F-AlF-PSMA-11的标记采用Boschi等与Malik等描述的18F-AlF络合方法并作小幅修改。
  • 评估了乙醇、乙腈和三氟乙酸对18F-AlF-PSMA-11标记产物稳定性的影响。

临床怎么用

  • 18F-AlF-PSMA-11可用于PSMA表达肿瘤的PET/CT显像,肿瘤摄取与68Ga-PSMA-11相近。
  • 制备与使用中需关注其在水中的不稳定性,控制注药时放化纯度以减少骨内Al18F摄取。
  • 对前列腺癌小骨转移灶的判读需警惕因骨摄取造成的假阳性或显示不清。

局限性

  • 研究为动物(荷瘤裸鼠)与体外实验,未在患者中验证。
  • 原文未报告骨摄取升高对骨转移灶判读影响的定量评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim was to compare the prostate-specific membrane antigen (PSMA)-targeting characteristics of PSMA-11, radiolabeled on the basis of chelation of 18F-AlF, with those of 68Ga-PSMA-11 to image PSMA-expressing xenografts. Methods: Labeling of 18F-AlF-PSMA-11 via 18F-AlF-complexation was performed as described by Boschi et al. and Malik et al. with minor modifications. Several conditions for the quality control of the labeling of 18F-AlF-PSMA-11 via 18F-AlF-complexation were evaluated to characterize the influence of ethanol, acetonitrile, and trifluoroacetic acid on the stability of the labeled product. Internalization kinetics of 18F-AlF-PSMA-11 were compared with those of 68Ga-PSMA-11 using PSMA-expressing LNCaP tumor cells. Biodistribution of 18F-AlF-PSMA-11 (0.26 nmol/mouse, 8-9 MBq/mouse) in male BALB/c nude mice with PSMA-expressing subcutaneous LS174T-PSMA tumors was compared with that of 68Ga-PSMA-11 at 1 and 2 h after injection. In addition, 18F-AlF-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/CT imaging were performed at 1 and 2 h after injection. Results: In contrast to 68Ga-PSMA-11, 18F-AlF-PSMA-11 was not stable in water (radiochemical purity was 64.5% immediately after purification and 52.7% at 120 min after purification). 18F-AlF-PSMA-11 remained relatively stable in 25 mM NH4OAc, pH 6.9, and radiochemical purity decreased from 98.5% at purification to 96.3%, 94.7%, and 92.5% at 60, 120, and 180 min after purification. In vitro, the 18F- and 68Ga-labeled compounds showed rapid internalization in LS174T-PSMA cells. The highest tumor uptake (percentage injected dose [%ID]) was observed at 2 h after injection (10.8 ± 2.3 %ID/g and 7.9 ± 1.3 %ID/g for 18F-AlF-PSMA-11 and 68Ga-PSMA-11, respectively [P > 0.05]). Renal tracer uptake peaked at 2 h after injection (43.5 ± 5.7 %ID/g and 105.8 ± 13.8 %ID/g for 18F-AlF-PSMA-11 and 68Ga-PSMA-11, respectively, P < 0.05). Bone uptake of 18F-AlF-PSMA-11 was 3.3 ± 0.6 at 1 h after injection and 5.0 ± 0.6 %ID/g at 2 h after injection and was dependent on the radiochemical purity at the time of injection. Bone uptake of 68Ga-PSMA-11 reached 0.1 ± 0.0 %ID/g at 1 and 2 h after injection. PSMA-expressing xenografts could be visualized using both 68Ga-PSMA-11- and 18F-AlF-PSMA-11 PET/CT. Conclusion: 18F-AlF-PSMA-11 using direct labeling with aluminum fluoride can be produced in NH4OAc, pH 6.9; shows a high internalization rate; and visualizes PSMA-expressing tumors with similar tumor uptake. Lower kidney uptake than with 68Ga-PSMA-11 may be advantageous for tumor detection. However, the limited instability and consequent Al18F uptake in bone might hamper the visualization of small PCa bone metastases.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lütje S, Franssen GM, Herrmann K, et al. In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts. J Nucl Med. 2019. PMID: 30655329. doi:10.2967/jnumed.118.218941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。